A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Shares of Celcuity surged more than 186% on Monday after the biotechnology company reported highly positive topline results ...

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to ...

By Mariam Sunny (Reuters) -Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's ...

Celcuity shares skyrocketed to an all-time high when the biotech reported positive results from a Phase 3 trial of its ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

Celcuity’s stock jumps after Phase 3 trial shows gedatolisib slashes progression risk in breast cancer patients by up to 76%.

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, ...

Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single ...

The drug, gedatolisib, in combination with Pfizer's Ibrance and AstraZeneca's endocrine therapy Faslodex, reduced the risk of ...

Investing.com -- Celcuity Inc. (NASDAQ: CELC) stock surged over 100% following the announcement of positive Phase 3 trial results for its breast cancer drug gedatolisib, which showed unprecedented ...